IBS C News and Research

RSS

Hard-core smokers most strongly influenced by genetic factors

A new study of twins led by the University of Colorado Boulder shows that today's smokers are more strongly influenced by genetic factors than in the past and that the influence makes it more difficult for them to quit.

17 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

Targeted antibiotic safe and effective for irritable bowel syndrome

Among the most commonly used treatments for irritable bowel syndrome - which affects as many as 20 percent of the United States population - a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai researchers, based on an analysis of 26 large-scale clinical trials.

2 Nov 2011

Emotional and psychological traumas may contribute to adult IBS

The psychological and emotional traumas experienced over a lifetime--such as the death of a loved one, divorce, natural disaster, house fire or car accident, physical or mental abuse—may contribute to adult irritable bowel syndrome (IBS), according to the results of a study unveiled today at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC.

1 Nov 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

Synergy commences plecanatide Phase II/III trial in chronic idiopathic constipation

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced initiation of dosing of patients in a major Phase II/III clinical trial of plecanatide to treat chronic idiopathic constipation.

24 Oct 2011

FDA accepts Ironwood and Forest Laboratories' linaclotide NDA for review

Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation.

24 Oct 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

Almirall seeks European approval for linaclotide to treat irritable bowel syndrome with constipation

Almirall, S.A. announced today that it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for linaclotide, an investigational guanylate cyclase-C (GC-C) receptor agonist for the treatment of irritable bowel syndrome with constipation (IBS-C). Once approved, linaclotide will be marketed in Europe under the trademark Constella®.

29 Sep 2011

Almirall submits linaclotide MAA to EMA for treatment of IBS-C

Ironwood Pharmaceuticals, Inc. today announced that its European partner Almirall, S.A. submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for linaclotide, a guanylate cyclase type-C (GC-C) agonist, for the treatment of irritable bowel syndrome with constipation.

29 Sep 2011

Neuroticism affects brain processing during anticipation and experience of pain

Neuroticism - the tendency to experience negative emotions -significantly affects brain processing during pain, as well as during the anticipation of pain, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Neuroticism tends to be higher in patients with irritable bowel syndrome (IBS), and is a risk factor for chronic, unexplained pain in IBS.

20 Sep 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

Irritable Bowel Syndrome linked to bacterial overgrowth, food poisoning

Cedars-Sinai researchers have reported two advances in the understanding of Irritable Bowel Syndrome, the most common gastrointestinal disorder in the United States, affecting an estimated 30 million people.

12 May 2011

UNC researchers present latest advances in GI, medicine and technology at DDW 2011

Digestive Disease Week is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

10 May 2011

Abbott, Sucampo present lubiprostone phase 3 trial data in Japanese CIC at DDW 2011

Sucampo Pharmaceuticals, Inc. and Abbott today reported data from a phase 3 clinical efficacy trial in 124 Japanese chronic idiopathic constipation patients as well as from a phase 3 long-term safety trial in an additional 209 Japanese CIC patients.

10 May 2011

Bioniche Life Sciences opens new livestock vaccine manufacturing facility

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today officially opened its new Animal Health and Food Safety Vaccine Manufacturing Centre at its corporate headquarters in Belleville, Ontario, Canada.

30 Apr 2011

GPs could offer simple test for early detection of ovarian cancer

Health experts have said that hundreds of lives could be saved a year if GPs were quicker to spot symptoms of the disease - dubbed a “silent killer” because it is hard to diagnose early enough. Ovarian cancer kills almost 4,400 women in Britain every year. It kills one every two hours that makes it the fourth most common cancer in females. While almost three times as many die from breast cancer, those diagnosed with ovarian cancer are far more likely to die earlier.

28 Apr 2011

How peppermint helps to relieve Irritable Bowel Syndrome

University of Adelaide researchers have shown for the first time how peppermint helps to relieve Irritable Bowel Syndrome, which affects up to 20% of the population.

20 Apr 2011

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011